Skip to Content

Mefloquine and tafenoquine information

The Department of Veterans' Affairs (DVA) offers a range of support for current and former Australian Defence Force (ADF) personnel who are concerned about having taken mefloquine (trade name Lariam) or tafenoquine.

Mefloquine and Tafenoquine Consultation Forums

Text reads: Mefloquine and Tafenoquine Outreach Program

The Department of Veterans' Affairs (DVA) will be holding a series of Mefloquine and Tafenoquine Consultation Forums across Australia from September 2018.

The purpose of these forums will be to provide an opportunity to hear from current and former serving members and outline the treatment, services and support available. This will help DVA to better understand the needs of those who have concerns about these medications and to direct them quickly to available treatment options.

Information will also be provided on currently available services and supports, with DVA, Defence and Open Arms - Veterans & Families Counselling staff present to arrange one-on-one assistance if required.

The first consultation forum was held in Adelaide on 26 September 2018. DVA will be holding forums  in the locations listed in the table below. You can register to attend one of these forums by emailing your contact details to the  email address listed in the following table.

Mefloquine and Tafenoquine Consultation Forums
State Date Email address to register
Sydney Monday, 29 October 2018 Clients.Benefits.Div.Coord@dva.gov.au
Brisbane Tuesday, 30 October 2018 Qld.Exec.Supp@dva.gov.au
Townsville Wednesday, 7 November 2018 Qld.Exec.Supp@dva.gov.au
Perth Tuesday, 13 November 2018 DCWA@dva.gov.au
Melbourne Thursday, 15 November 2018 Deputy.Commissioner.VIC.Coord@dva.gov.au
Darwin Tuesday, 27 November 2018 CSA.NT@dva.gov.au

If you are outside of the locations listed above, you can register your interest by emailing your contact details, including your location, to the relevant State contact email listed below.

Mefloquine and Tafenoquine Consultation Forums
State Email address to register
New South Wales and the Australian Capital Territory Clients.Benefits.Div.Coord@dva.gov.au
Northern Territory CSA.NT@dva.gov.au
Queensland Qld.Exec.Supp@dva.gov.au
Tasmania Deputy.Commissioner.Tas.Coord@dva.gov.au
Victoria Deputy.Commissioner.VIC.Coord@dva.gov.au
Western Australia DCWA@dva.gov.au

 

About Mefloquine and Tafenoquine

DVA recognises mefloquine and tafenoquine as being associated with several health conditions under the Statements of Principles (SoPs) system that applies to treatment and compensation claims.

For a summary on mefloquine and tafenoquine and the resources and support available (including relevant web links, phone numbers and email addresses), download one of the following:

For more information visit Malaria, mefloquine and the ADF.

Support available

1800 MEFLOQUINE (1800 633 567)

DVA has a designated phone line — 1800 MEFLOQUINE (1800 633 567) — for veterans with enquiries, including upcoming consultation forums and other available support.

Medicare-rebated health assessment

All former serving personnel can access a comprehensive health assessment from their GP. Ex-service personnel can access this one-off health assessment at any stage after leaving the ADF, as there are no time restrictions.

A key objective of this comprehensive health assessment is to help the GP identify and diagnose the early onset of any physical or mental health conditions. GPs will then be able to treat or refer their patients to other services, as necessary.

A Medicare rebate is available for this assessment.

Mental health treatment

DVA can pay for treatment for any mental health condition without the need for the conditions to be accepted as related to service. This is known as non-liability health care and it is available to anyone with one day of continuous full-time service in the ADF.

Open Arms - Veterans & Families CounsellingLogo - Open Arms - Veterans & Families Counselling

Open Arms - Veterans & Families Counselling also provides free, confidential, nationwide counselling and support for eligible current and former ADF members and their families and can be contacted 24/7 on 1800 011 046.
 

Free online tools

Mental health information and resources for veterans and their families are available through At Ease — DVA's portal to online mental health information.

At Ease provides self-help tools and information to support mental health and wellbeing and is a gateway to websites and mobile apps about stress, PTSD, alcohol management, resilience and suicide awareness and prevention. The apps include High Res, which helps build resilience and manage stress, Operation Life for those managing suicidal thoughts and On Track with The Right Mix, which helps people track and manage their drinking.

For a summary of DVA's online resources, download a copy of the handout from one of the following links:

At Ease also provides links to a wide range of mental health resources for health professionals and GPs for effective evidence-based treatment of veterans.

For general practitioners

Defence and DVA encourage general practitioners (GPs) to review Defence Joint Health Command's Clinical Guidelines for providing appropriate care to ADF members concerned about having been prescribed mefloquine. While there is no specific way to diagnose the long-term effects of mefloquine and no specific treatment, other than to treat presenting symptoms, these guidelines outline a commonsense approach to the management of individuals who are concerned their current problems may be caused by mefloquine use in the ADF.

Claiming

Current and former members of the ADF who have a diagnosed health condition that they believe relates to mefloquine or tafenoquine can lodge a claim with DVA.

To lodge a claim or for assistance with mefloquine- or tafenoquine-related claims, call DVA on 1800 MEFLOQUINE (1800 633 567) or visit DVA's online Entitlement Self-Assessment tool.

When a claim is accepted, current and former ADF members can access treatment and rehabilitation support.

Access to mental health treatment is available immediately, when required, and is separate to DVA's compensation process.

DVA assesses compensation claims under three pieces of legislation, two of which use Statement of Principles (SoPs). SoPs are legislative instruments that state factors that must exist to establish a connection between a health condition and military service.

An independent statutory authority, the Repatriation Medical Authority (RMA), determines the SoPs.

Together, mefloquine and tafenoquine are included as a potential causal factor in the SoPs for 16 conditions. Of these, mefloquine is covered by 15 SoPs and tafenoquine is covered by six SoPs.

Mefloquine and tafenoquine as a potential causal factor in SoPs
Condition Anti-malarial medication
1. Anxiety disorder Mefloquine
2. Bipolar disorder Mefloquine
3. Depressive disorder Mefloquine
4. Heart block Mefloquine
5. Myasthenia gravis Mefloquine
6. Peripheral neuropathy Mefloquine
7. Schizophrenia Mefloquine
8. Suicide and attempted suicide Mefloquine
9. Trigeminal neuropathy Mefloquine
10. Epileptic seizure Mefloquine and Tafenoquine
11. Acquired cataract Mefloquine and Tafenoquine
12. Sensorineural hearing loss Mefloquine and Tafenoquine
13. Tinnitus Mefloquine and Tafenoquine
14. Psoriasis Mefloquine and Tafenoquine
15. Methaemoglobinaemia Tafenoquine
16. Toxic retinopathy Mefloquine

Claims that do not use the SoPs are determined based on specialist medical opinion.

Repatriation Medical Authority investigation and the Specialist Medical Review Council

The Repatriation Medical Authority (RMA) investigated mefloquine as a cause of panic disorder. It found that panic attacks resulting from medications belong under a diagnosis of 'medication-induced anxiety disorder' and are covered by a new factor in the anxiety disorder SoP. As such, there is no new factor relating to mefloquine in the panic disorder SoP.

The RMA investigated whether SoPs may be determined in respect of 'chemically-acquired brain injury caused by mefloquine, tafenoquine and primaquine'. The RMA found that there is insufficient sound medical-scientific evidence that exposure to these pharmaceuticals causes acquired brain injury and, therefore, will not make SoPs in relation to this. The report is available via the RMA.

On 18 September 2018, the Specialist Medical Review Council (SMRC) completed its review of the RMA investigation and it confirmed the RMA's decision. For further information visit SMRC Decisions.

Average: 2.3 (8 votes)